Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show
Spring on the Road
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
89Bio Inc
(NQ:
ETNB
)
7.690
-0.160 (-2.04%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 13, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about 89Bio Inc
< Previous
1
2
3
4
5
6
7
8
9
Next >
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 29, 2024
From
89bio, Inc.
Via
GlobeNewswire
89bio to Participate in the 7th Annual Evercore HealthCONx Conference
November 26, 2024
From
89bio, Inc.
Via
GlobeNewswire
89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting® 2024
November 15, 2024
New post-hoc analyses reinforce pegozafermin’s potential anti-fibrotic effects and the potential utility of non-invasive tests which correlate to histological endpoints
From
89bio, Inc.
Via
GlobeNewswire
ETNB Stock Earnings: 89bio Beats EPS for Q2 2024
August 05, 2024
ETNB stock results show that 89bio beat analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
ETNB Stock Earnings: 89bio Misses EPS for Q1 2024
May 09, 2024
ETNB stock results show that 89bio missed analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
89bio, Inc. Announces Upsized Pricing of $125.0 Million Public Offering of Common Stock and Pre-Funded Warrants
November 12, 2024
From
89bio, Inc.
Via
GlobeNewswire
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
November 12, 2024
From
89bio, Inc.
Via
GlobeNewswire
89bio Reports Third Quarter 2024 Financial Results and Corporate Updates
November 07, 2024
From
89bio, Inc.
Via
GlobeNewswire
89bio to Participate in the UBS Global Healthcare Conference
November 05, 2024
From
89bio, Inc.
Via
GlobeNewswire
Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH
November 01, 2024
Madrigal sells an approved MASH treatment that blasted third-quarter sales views out of the water.
Via
Investor's Business Daily
89bio to Present New Analyses from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at AASLD The Liver Meeting® 2024
October 15, 2024
From
89bio, Inc.
Via
GlobeNewswire
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 11, 2024
From
89bio, Inc.
Via
GlobeNewswire
89bio to Participate in the H.C. Wainwright 8th Annual MASH Investor Conference
September 30, 2024
From
89bio, Inc.
Via
GlobeNewswire
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 19, 2024
From
89bio, Inc.
Via
GlobeNewswire
89bio Announces Appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality Officer
September 16, 2024
From
89bio, Inc.
Via
GlobeNewswire
89bio to Participate in Upcoming Investor Conferences
August 29, 2024
From
89bio, Inc.
Via
GlobeNewswire
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 09, 2024
From
89bio, Inc.
Via
GlobeNewswire
89bio Appoints Francis Sarena as Chief Operating Officer
August 07, 2024
From
89bio, Inc.
Via
GlobeNewswire
89bio Reports Second Quarter 2024 Financial Results and Corporate Updates
August 05, 2024
From
89bio, Inc.
Via
GlobeNewswire
89bio Appoints Charles McWherter, Ph.D., to its Board of Directors
August 05, 2024
From
89bio, Inc.
Via
GlobeNewswire
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 12, 2024
From
89bio, Inc.
Via
GlobeNewswire
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 14, 2024
From
89bio, Inc.
Via
GlobeNewswire
What's Going On With Fattly Liver Disease Focused Madrigal Pharmaceuticals, Sagimet Biosciences Shares On Wednesday?
June 05, 2024
Madrigal Pharmaceuticals and Sagimet Biosciences shares fall following Eli Lilly's presentation at the EASL Liver Congress 2024. Phase 2 tirzepatide trial shows promising results for MASH treatment....
Via
Benzinga
Madrigal, Akero, 89bio Tumble After Lilly's Weight-Loss Drug Tackles MASH
June 05, 2024
Researchers published results Wednesday showing Lilly's weight-loss drug could work in a liver disease.
Via
Investor's Business Daily
The Week Ahead: What's Next
June 02, 2024
The core part of our portfolio is up 24% this year ... and we're about to add another stock. Plus, a riddle.
Via
Talk Markets
89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver Congress
May 22, 2024
-Poster presentation selected for the EASL Poster Tour, a dedicated discussion session-
From
89bio, Inc.
Via
GlobeNewswire
89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated Cirrhosis
May 14, 2024
From
89bio, Inc.
Via
GlobeNewswire
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 10, 2024
From
89bio, Inc.
Via
GlobeNewswire
89bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 09, 2024
From
89bio, Inc.
Via
GlobeNewswire
89bio to Participate in the BofA Securities 2024 Health Care Conference
May 08, 2024
From
89bio, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.